Evaluating clinical meaningfulness of anti-β-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer’s disease
2024

Evaluating the Effectiveness of Anti-β-Amyloid Therapies in Alzheimer's Disease

Sample size: 1653 publication 10 minutes Evidence: moderate

Author Information

Author(s): Manal Aljuhani, Ashraf Azhaar, Edison Paul

Primary Institution: Prince Sattam Bin Abdulaziz University

Hypothesis

What is the clinical meaningfulness of anti-β-amyloid therapies amidst concerns of amyloid-related imaging abnormalities in Alzheimer's disease?

Conclusion

Anti-β-amyloid therapies can slow cognitive decline in Alzheimer's disease but are associated with significant risks of adverse events.

Supporting Evidence

  • Monoclonal antibodies against β-amyloid can slow clinical decline by 25-40%.
  • Adverse events like amyloid-related imaging abnormalities can occur early in treatment.
  • Clinical trials showed that lecanemab and donanemab received FDA approval based on their efficacy.

Takeaway

This study looks at how certain treatments for Alzheimer's disease can help people think better, but they can also cause some serious side effects.

Methodology

The review evaluates clinical trial results and safety concerns associated with anti-β-amyloid therapies.

Potential Biases

Potential biases may arise from unblinding and dropout rates in clinical trials.

Limitations

The study's findings may not be generalizable to all Alzheimer's patients due to the selective nature of clinical trial participants.

Participant Demographics

Participants included individuals with early Alzheimer's disease, with a focus on racial and ethnic diversity.

Statistical Information

P-Value

0.012

Confidence Interval

95% CI not specified

Statistical Significance

p=0.012

Digital Object Identifier (DOI)

10.1093/braincomms/fcae435

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication